<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A1
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A1
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A1
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lloyd Axelrod, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 21, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          ANSWER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incorrect.
        </p>
        <p>
         In general, the addition of a third oral antidiabetic agent in a patient with a glycated hemoglobin (A1C) value of 9.2 percent is unlikely to achieve the goal of reducing the A1C to &lt;7.0 percent.
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          Pioglitazone
         </a>
         , a thiazolidinedione, is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) modulator. It reduces the A1C value by 0.5 to 1.4 percent when used as monotherapy. It is unlikely to reduce the A1C by more than this in a patient who is taking two other oral agents. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Dual agent failure'
         </a>
         .)
        </p>
        <p>
         The thiazolidinediones are difficult to use because their effect on glucose levels and A1C values may not be apparent for two to three months. The use of three oral agents is often more expensive than insulin plus
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         when a less expensive insulin such as NPH is used. These agents cause weight gain and fluid retention and increase the risk of congestive heart failure. They should not be used in patients with a history of congestive heart failure or chronic kidney disease.
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          Pioglitazone
         </a>
         causes an increased risk of fractures of the upper arms, hands, and feet, particularly in female patients with diabetes.
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          Rosiglitazone
         </a>
         , another agent in the same class, may cause an increased risk of myocardial infarction. For all these reasons, thiazolidinediones are not recommended for the treatment of diabetes. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p>
         Return to the beginning to try again. (See
         <a class="medical medical_review" href="/z/d/html/4176.html" rel="external">
          "Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents"
         </a>
         .)
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 4210 Version 8.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
